Gilead Still High Blood Pressure (GILD)

Posted in pre-market 
December 15th, 2009

Gilead Sciences Inc. (NASDAQ: GILD) was halted earlier this morning.  The company’s darusentan missed its Phase III study endpoints in the tests for a new blood pressure medication.  At 7:40 AM EST volume is still rather light but shares are trading down under $46.00 after a $46.96 close on 17,000 shares.  Gilead’s 52-week trading range is $40.62 to $53.28.  You can expect volume to increase substantially after 8:00 AM EST and as we get closer to the 9:30 AM opening bell as the average daily trading volume is about 7.2 million shares. -Jon Ogg

Comments are closed